We are live on ! Find out more

Editas Medicine

EDIT

Market cap $425M

2.77 USD

+0.05

1.84%

At close Updated Sep 18, 2:11 PM EDT

1 day

1.84%

5 days

1.84%

1 month

-3.82%

3 months

2.97%

6 months

17.87%

Year to date

35.12%

1 year

-7.67%

5 years

-95.24%

10 years

-81.22%

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Employees: 87

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 72.7%

Negative 0%

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Zacks Investment Research

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September: Wells Fargo Healthcare Conference Format: Fireside ChatDate: Tuesday, September 8Time: 4:30 p.m.

Editas Medicine to Participate in Upcoming Investor Conferences

Zacks Investment Research

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Zacks Investment Research

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.63 per share a year ago.

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates Recent financing strengthens Company's capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the second quarter 2026 and provided business updates.

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

See News Rankings

Price charts implemented using Lightweight Charts™